BRINGING NOVEL INVESTIGATIONAL TREATMENTS FOR ECZEMA, ASTHMA and cancer ONE STEP CLOSER TO APPROVAL
Clinical trials are an important part of providing new medicines to those who need them. Learn more about each of our clinical trials below.
Zelnecirnon (RPT193) for the treatment of eczema (atopic dermatitis)
RAPT Therapeutics is developing a potential treatment called zelnecirnon for eczema.
Zelnecirnon (RPT193) for the treatment of asthma
RAPT Therapeutics is developing a potential treatment called zelnecirnon for asthma.
Tivumecirnon (FLX475) FOR THE TREATMENT OF CANCER
RAPT Therapeutics is developing a potential treatment called tivumecirnon alone and/or in combination with KEYTRUDA® (pembrolizumab).
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp.